Hi BaldwidxWhat I heard Jon say was that phase 2b trials were...

First 156 Last

Share
Profile

Follow
lost28

74 Posts.

22

28/05/24

14:49

Post #: 74046133
Share

Originally posted by baldwidx: ↑

Eagle - I wonder if you or some other posters might have more insight into the following.

Do you know if you can go straight to a P3 trial for an indication, in a drug that has been proven to be safe and effective? For example, if we get PMS and PHS through registration and into sales, presumably the FDA has deemed the drug to be not just effective v placebo, but safe.

JP referenced this yesterday when he mentioned not needing to undertake P2 trials given they are mainly used to determine dosing and safety. If we take appropriate dosing as a given, following his comments and if we take safety as a given, especially if we took one or both conditions through registration, then is it possible that we have a "straight to P3" pass?

If that is possible, then I think that SIGNIFICANTLY changes the landscape for Neuren - I can't see a TO being accepted unless its absolutely astronomical - numbers we don't even dare to discuss. Why would you not run through P3 after P3 yourself and keep all the profit??

if you have sufficient funds in the short term to run the PMS and PHS trials through to marketing, you may need a small CR (pending updated Daybue Revenue) to keep the lights running but you would quickly bring in so much money from those two that can be reinvested into AMS and then PWS and so on.

It really does shift the paradigm but I guess its all predicated on whether a "straight to P3" scenario is possible.

Has anyone come across it before in a similar platform drug?

Expand

Hi Baldwidx
What I heard Jon say was that phase 2b trials were all about refining dosage not phase 2.

NEU Price at posting: $23.12 Sentiment: None Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

LU7

Lithium Universe leaps 40% after buying rights to flashy solar panel recycling tech

Almonty Industries – Now it is getting critical!

ASX Market Open: Shares down as Trump threatens 'real end' to Israel-Iran conflict | June 18

MEM

Many are concerned about global falling birthrates. This diverse stock has solutions

First 156 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $13.21		Change 0.360(2.80%)		Mkt cap ! $1.626B

Open	High	Low	Value	Volume
$13.15	$13.28	$12.92	$2.945M	225.2K

Buyers (Bids)

No.	Vol.	Price($)
1	928	$13.20

Sellers (Offers)

Price($)	Vol.	No.
$13.22	127	3

View Market Depth

No.	Vol.	Price($)
18	825	13.190
4	187	13.180
5	533	13.170
11	1609	13.160
5	1308	13.150

Price($)	Vol.	No.
13.200	36	3
13.210	221	5
13.220	494	3
13.230	508	3
13.240	1237	4

Last trade - 11.20am 18/06/2025 (20 minute delay)

NEU (ASX) Chart

Hi BaldwidxWhat I heard Jon say was that phase 2b trials were...

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Lithium Universe leaps 40% after buying rights to flashy solar panel recycling tech

Almonty Industries – Now it is getting critical!

ASX Market Open: Shares down as Trump threatens 'real end' to Israel-Iran conflict | June 18

Many are concerned about global falling birthrates. This diverse stock has solutions

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Hi BaldwidxWhat I heard Jon say was that phase 2b trials were...

Top Stories

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Lithium Universe leaps 40% after buying rights to flashy solar panel recycling tech

Almonty Industries – Now it is getting critical!

ASX Market Open: Shares down as Trump threatens 'real end' to Israel-Iran conflict | June 18

Many are concerned about global falling birthrates. This diverse stock has solutions

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News